We previously identified conserved G/C Repressor elements in the promoters of most smooth muscle cell (SMC) marker genes and demonstrated that mutation of this element within the SM22␣ promoter nearly abrogated repression of this transgene after vascular wire injury or within lesions of ApoE؊/؊ mice. However, the mechanisms regulating the activity of the G/C Repressor are unknown, although we have previously shown that phenotypic switching of cultured SMC is dependent on Krupple-like factor (KLF)4.
of cultured SMC in response to platelet-derived growth factor (PDGF)-BB, PDGF-DD, and oxidized phospholipids is dependent on the embryonic stem cell (ESC) pluripotency Krupplelike factor (KLF)4, including (1) expression of KLF4 was increased after treatment of cultured SMC with these factors 8,14,35-38 ; (2) siRNA-induced suppression of KLF4 inhibited suppression of SMC marker genes 8,38 -40 ; and (3) overexpression of KLF4 in cultured SMC was associated with coordinate downregulation of SMC marker genes and the SMC-specific SRF coactivator myocardin, 39, 40 and epigenetic silencing of SMC marker gene loci. 30, 31, 33, 34 However, the preceding studies were conducted almost exclusively in cultured SMCs that have already undergone extensive phenotypic switching. Moreover, it is clear that these simple in vitro models of SMC phenotypic switching fail to recapitulate complex environmental cues that mediate SMC phenotypic switching in vivo. As such, very little is known regarding mechanisms and factors that regulate SMC phenotypic switching in vivo after vascular injury or in disease models, including atherosclerosis.
A major advance in understanding the mechanisms that regulate SMC phenotypic switching in vivo were studies from our laboratory showing that suppression of the SMC marker gene SM22␣ after vascular injury or within atherosclerotic lesions of ApoEϪ/Ϫ mice was dependent on a G/C Repressor element located in proximity to SM22␣ 5Ј CArG boxes. 41, 42 Notably, mutation of the conserved G/C Repressor element did not alter developmental expression of this gene in transgenic mice 41 but nearly completely abrogated down regulation of the gene after carotid wire injury 41 or within atherosclerotic lesions. 42 However, studies failed to identify the transcription factors and mechanisms that regulate the activity of the G/C Repressor element, a regulatory element found within promoters of nearly all CArG-dependent SMC marker genes.
There are a number of transcription factor families capable of binding to G/C rich elements, including Sp1 and Kruppellike zinc finger transcription factors. 43 The Owens laboratory first tested Sp1 and Sp3 as potential G/C Repressor binding factors because they are expressed in SMCs and are induced during PDGF-BB phenotypic switching of cultured SMCs. 41, 42 Interestingly, Sp1 can bind to the SM22␣ G/C Repressor in electrophorectic mobility shift assays (EMSA), and siRNA suppression of Sp1 inhibited phenotypic switching in cultured SMCs in response to PDGF-BB. However, we were unable to demonstrate direct binding of Sp1 to SMC marker gene promoters within intact chromatin by Chromatin immunoprecipitation (ChIP) assays after PDGF-BB treatment or in vivo after vascular ligation injury. 41, 42 Moreover, we subsequently showed that Sp1 dependence of SMC phenotypic switching in cultured SMC was mediated by Sp1-dependent activation of KLF4, whose promoter contains three conserved Sp1 binding sites. 45 KLF4 is an attractive alternative candidate given that we have previously shown that it is required for SMC phenotypic switching of cultured SMC. 8,30 -32,38 -40,45 Moreover, we demonstrated increased KLF4 binding to SMC promoters after carotid ligation injury in vivo and that global conditional KLF4 knockout mice showed a transient delay in SMC phenotypic switching after carotid ligation injury in vivo. 32 However, we have been unable to show specific binding of KLF4 to the SM22␣ G/C repressor based on EMSA. Furthermore, the effects of global knockout of KLF4 on SMCs may be mediated indirectly through loss of KLF4 in (1) macrophages where it mediates monocyte to macrophage differentiation 46,47,48 and/or (2) in endothelial cells where it has proinflammatory effects including mediating activation of leukocyte adhesion molecules. 49, 50 Thus, at present, there is no direct evidence indicating that the activity of the SM22␣ G/C Repressor in vivo during vascular injury is dependent on KLF4 or mediated through direct binding of KLF4 to the G/C repressor element. The present studies test the hypothesis that repression of SM22␣ expression during SMC phenotypic switching in vivo after carotid ligation is mediated through binding of pELK-1 (downstream activator of the mitogen-activated protein kinase pathway) and KLF4 to the G/C Repressor element. We also hypothesize that the pELK-1-KLF4 complex in turn recruits histone de-acetylases (HDACs) to this gene locus and mediates epigenetic silencing. Finally, given evidence that many SMC marker genes contain G/C Repressor elements, we postulate that these mechanisms contribute to coordinate suppression of multiple SMC genes during SMC phenotypic switching.
Methods
Animal protocol models were approved by the University of Virginia Animal Care and Use Committee. An expanded Materials and Methods section is available in the online-only Data Supplement. 
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Results
Suppression of SM22␣ Gene Expression After Carotid Ligation Is G/C Repressor Dependent
We previously demonstrated that mutation of the SM22␣ G/C Repressor element inhibited repression of this gene during SMC phenotypic switching after carotid wire injury 41 or within atherosclerotic lesions of ApoEϪ/Ϫ Western diet-fed mice. 42 Given evidence that SMC phenotypic switching after carotid ligation is KLF4-dependent, 32 we first determined if suppression of SM22␣ in this model is also G/C Repressor dependent. Carotid ligations were done in SM22␣ wild-type (WT) and SM22␣ G/C Repressor mutant LacZ transgenic mice. 41 X-gal staining was examined 3 days after ligation, a time point we previously demonstrated that there is significant loss of expression of the endogenous SM22␣ gene in this model. 32 Results showed that mutation of the G/C Repressor nearly abolished downregulation of SM22␣ after ligation injury ( Figure 1A and 1B). The unligated left carotid of both SM22␣ WT and SM22␣ G/C Repressor mutant LacZ transgenic mice showed no repression and exhibited SMC restricted expression, indicating that the mutation had no discernible effects on expression in differentiated (nonpheno-typically modulated) SMC, consistent with our previous observations showing normal developmental expression of the mutant transgene. 41 Taken together, these results, and those of our previous studies demonstrate that the G/C Repressor element is required for downregulation of SM22␣ gene expression in ALL models of SMC phenotypic switching examined to date. Given the diversity of these models, it is thus likely that G/C Repressor dependent SMC phenotypic switching represents a common transcriptional regulatory pathway for SMC phenotypic switching across highly divergent stimuli. To further test this possibility, we determined the importance of the G/C Repressor element in 2 in vitro models of SMC phenotypic switching, treatment with PDGF BB, 9, 10, 14, 39 and the proatherogenic oxidized phospholipid POVPC. 8, 38 The SM22␣ G/C Repressor mutant promoter reporter showed attenuated PDGF-BB and POVPC induced repression as compared with the WT SM22␣ promoter reporter, although both showed some repression consistent with previous reports that there are also G/C Repressor independent mechanisms operative within these in vitro models, 41, 42 although it remains to be shown they are functional in vivo.
Figure 1. SM22 G/C Repressor mutant
LacZ transgene fails to downregulate after vascular ligation injury in vivo. A, SM22 and SM22 G/C mut LacZ mice were subjected to right common carotid ligation injury. The right and left carotids were harvested 3 days after injury, fixed, X-gal-stained, and a gross morphological image was taken. B, Carotid arteries from A were embedded in paraffin, sectioned, and stained as previously described. 41 Each picture is a representative image from nϭ5 animals. C, Rat aortic smooth muscle cells were plated and then transiently transfected with LT-Mirus 24 and 300 ng of ␣-actin or SM22 or SM22 with a mutant GC repressor element. 24 hours after transfection cells were treated with PDGF-BB. Twenty-four hours after treatment, cells were harvested and LacZ activity and protein activity were measured. Asterisk indicates significant downregulation of the WT versus the G/C Repressor mutant as mentioned in the Methods section. D, Cells were treated as mentioned in C. Twenty-four hours after transfection, cells were treated with POVPC. Cells were harvested and assayed as mentioned in C.
KLF4 Binds the G/C Repressor Element In Vivo After Vascular Ligation Injury
We have previously shown enriched binding of KLF4 to SM22␣ and other SMC promoters after carotid ligation in vivo. 32 However, there is no direct evidence that this binding was G/C Repressor dependent. To test if KLF4 binding in vivo is G/C Repressor dependent, we performed ChIP assays after carotid ligation in SM22␣ WT and SM22␣ G/C Repressor mutant LacZ transgenic mice. Given limited availability of transgenic mice, and the requirement of 10 mouse carotids for each in vivo ChIP data point, we first determined the kinetics of KLF4 binding to the endogenous SM22␣ promoter region using C57/B6 control mice. Ligated right carotids and control left carotid arteries were harvested at 1, 3, 7, 14, and 21 days after vascular ligation injury. Consistent with our previous results, 32 we observed enhanced binding of KLF4 to the SM22␣ promoter region 1 and 3 days after vascular injury ( Figure 2A ). Binding was selective since KLF4 was not bound to an intronic sequence located within the SM22␣ promoter ( Figure 2B ). Further ChIP analyses on WT and G/C Repressor mutant mice 3 days after vascular ligation injury were completed to determine if KLF4 binding is G/C Repressor element dependent. As a control, KLF4 ChIP assays used PCR primers that distinguished the endogenous mouse SM22␣ promoter versus the rat SM22␣ promoter-LacZ transgenes (Online Figure I) . These experiments are important since we originally cloned KLF4 using a yeast one hybrid method based on its ability to bind to another G/C rich cis element located within 200 base pairs of the G/C Repressor element (the TCE element). 40, 45 The TCE element is located proximal to the first CArG element, whereas the G/C Repressor element is located proximal to the second CArG element (Online Figure  IVA) , and we have shown that mutation of these elements have profoundly different effects. 39, 41 That is, mutation of the TCE element completely abolished transgene expression in vivo in mice, whereas mutation of the G/C repressor had no effect on transgene expression during development and maturation but abrogated repression during SMC phenotypic switching. Results of SM22␣ in vivo ChIP analyses demonstrated enriched binding of KLF4 to the WT but not the G/C repressor mutant SM22␣ LacZ transgene and the endogenous SM22␣ promoter in both transgenic strains ( Figure 2C ). In contrast, Sp3 binding to the SM22␣ promoter was enhanced after carotid ligation but binding was not altered on the G/C Repressor mutation ( Figure 2D and Online Figure III ). As such, it is interesting to speculate that Sp3 might represent an alternate G/C Repressor-independent repressor pathway in cultured SMC ( Figure 1C and 1D) or in vivo. These in vivo ChIP assays provide clear evidence that enhanced binding of KLF4 to the SM22␣ promoter after carotid ligation is G/C Repressor dependent. The G/C Repressor is also required for suppression of SM22␣ during phenotypic switching of SMC after ligation injury (Figure 1 ), wire injury, 41 and within ApoEϪ/Ϫ atherosclerotic lesions. 42 Taken together, these results provide strong evidence that KLF4 plays an integral role in SMC phenotypic switching and functions through G/C Repressor-dependent mechanisms. Significantly, the preceding results are the first to provide direct evidence that the functional effects of mutating the G/C Repressor element (ie, virtually abrogating downregulation of SM22␣ in response to vascular injury or within atherosclerotic lesions) are causally linked to G/C Repressor dependent binding of KLF4.
Previously we showed that KLF4 repressed SMC marker gene expression in cultured SMC through multiple mechanisms, including (1) disruption of SRF and myocardin binding to SMC promoters within intact chromatin 39, 40, 45 and (2) induction of histone modifications associated with formation of heterochromatin and transcriptional silencing. 30, 31, 33, 34 However, we have not previously determined if these effects are G/C Repressor dependent, which is critical if we are to establish a causal relationship between KLF4 binding, epigenetic changes, and our observations that mutation of the G/C Repressor abrogated SM22␣ gene suppression in vivo during SMC phenotypic switching. We first tested if KLF4-induced repression of SM22␣ in cultured SMCs is G/C Repressor dependent via transient transfection assays using a KLF4 overexpression plasmid plus the WT or G/C Repressor mutant SM22␣ promoter LacZ. KLF4-induced repression of the SM22␣ promoter was markedly attenuated by mutation of the G/C Repressor ( Figure 3A ). We also performed ChIP assays in rat aortic SMCs stably transfected with the WT or G/C Repressor mutant SM22␣ promoter LacZ transgenes (Online Figure II) . KLF4 binding to the SM22␣ promoter was enhanced 12 hours after treatment of cultured SMC with either PDGF-BB ( Figure 3B ) or POVPC ( Figure 3C) , and binding was G/C Repressor dependent. Significantly, we showed that the G/C Repressor mutation itself did not result in decreased SRF binding (Online Figure IVB) and thereby contribute to transcriptional repression, consistent with our observations that expression of the G/C Repressor mutant LacZ transgene is normal in differentiated SMCs in vivo ( Figure 1 and Regan et al 41 ). However, SRF binding to the WT SM22␣ LacZ promoter and the endogenous SM22␣ promoter but not the G/C Repressor mutant was dramatically reduced in cultured SMCs Figure 3 . KLF4 binds to the SM22␣ LacZ transgene in vitro and binding is attenuated by mutation of the G/C Repressor element after PDGF-BB or POVPC treatment in rat aortic smooth muscle cells. A, Rat aortic smooth muscle cells were plated at 1ϫ10 Ϫ4 . 24 hours later cells were transiently transfected using LT-Mirus with 300 ng of SM22␣ WT or G/C Repressor MT and increasing concentrations of pcDNA-KLF4. Twenty-four hours after transfection, media was removed and replaced and 24 hours later cells were harvested and subjected to B-gal and protein assays. Results are the average of three independent experiments performed in triplicate. B and C, Rat aortic smooth muscle cells stably transfected with either SM22␣ or G/C Repressor mutant were plated at 1ϫ10 Ϫ4 and allowed to grow to confluence and then switched to serum-free media for 3 days. After serum starvation, cells were treated with 20 ng/mL PDGF-BB (B) or 5 g/mL of POVPC (C) for 12 hours and then subject to ChIP analysis. Asterisk indicates significant binding as mentioned in materials and methods. D, Cells were plated, and 24 hours after plating, cells were treated with either si-control or si-KLF4. Twenty-four hours after siRNA transfection, cells were treated with either vehicle or 20 ng/mL PDGF-BB for 12 hours. Cells were harvested, and ChIP analysis was performed as described in A. Asterisk indicates significant binding as mentioned in Figure 2D . treated with PDGF BB or POVPC (Online Figure IVB) , commensurate with increased G/C Repressor-dependent KLF4 binding (Online Figure IVC) . Finally, as an additional control for specificity of the KLF4 ChIP assays, we demonstrated that treatment of cultured SMC with a KLF4 siRNA resulted in markedly reduced KLF4 binding to the endogenous SM22␣ promoters, as well as the WT SM22␣ promoter LacZ transgene with/without PDGF-BB treatment ( Figure 3D ). Similar results were obtained in SMC treated with POVPC (data not shown). In contrast, KLF4 was found to be enriched on both the WT and the mutant TCE SM22␣ promoters after PDGF-BB (Online Figure  IVC) and POVPC treatment (data not shown), demonstrating that KLF4 binding is G/C Repressor specific. These results extend our previous studies showing that PDGF-BB-induced and POVPC-induced phenotypic switching of cultured SMC is dependent on KLF4 39, 40, 45 by demonstrating that effects are mediated through binding to the G/C Repressor thereby establishing for the first time evidence of a direct causal relationship between KLF4 binding to SMC promoters and the functional effects of mutation of the G/C Repressor preventing downregulation of SM22␣ during SMC phenotypic switching both in vivo and in vitro. Moreover, results validate our in vitro PDGF and POVPC models to further explore mechanisms by which KLF4 directly regulates the G/C Repressor.
pELK-1 Binds via the SM22␣ G/C Repressor Element 3 Days After Vascular Ligation Injury
Yoshida et al and others have demonstrated that pELK-1 binds to the SM22␣ promoter after PDGF-BB or POVPC treatment and that KLF4 and pELK-1 physically interact based on coim-munoprecipitation assays and sequential ChIP analysis. 16, 30, 31 pELK-1 also inhibits the interaction between SRF and myocardin by competing for same docking site on SRF as myocardin after PDGF-BB treatment. 16 The G/C Repressor and ETS binding site overlap by 3 base pairs within smooth muscle marker genes and we are physically unable to differentiate these sites (Online Figure IVA) . Therefore, we sought to determine (1) if there is enhanced binding of pELK-1 to the SM22␣ promoter after ligation injury in vivo, since previous studies by Wang et al were done exclusively in cultured cells, 16 and (2) if pELK-1 binding to the SM22␣ promoter is altered by mutation of the G/C Repressor. Right carotid ligation injuries were performed and carotid arteries subjected to pELK-1 ChIP analyses at 1, 3, 7, 14 and 21 days after injury ( Figure 4A ). Results showed enhanced pELK-1 binding at 1 and 3 days after carotid ligation-results identical to what we observed for KLF4 ( Figure  2A ). To determine if this enhanced pELK-1 binding was G/C Repressor dependent, we performed ChIP analyses in our SM22␣ WT, and G/C Repressor mutant SM22␣ promoter-LacZ transgenic mice. Results showed increased pELK-1 binding to the WT but not the G/C Repressor mutant SM22␣ transgene ( Figure 4B ), demonstrating that enhanced binding of pELK-1 to the SM22␣ promoter during SMC phenotypic switching in vivo is also G/C Repressor dependent. PDGF-BB or POVPC treatment resulted in increased pELK-1 binding to the endogenous and the WT SM22␣ LacZ transgene but not the G/C Repressor mutant SM22␣ promoter in cultured SMC ( Figure 4C and 4D) .
We also performed transient transfection assays to determine if overexpression of pELK-1 inhibited expression of the SM22␣ promoter (Online Figure V) . Overexpression of pELK-1 reduced Figure 2A and then subjected to ChIP analysis for pElk-1. Asterisk indicates significant binding compared with noninjured controls. Results are the average of 3 independent experiments. B, SM22 and SM22 G/C mut LacZ mice were subjected to right common carotid injury and then harvested 3 days after vascular injury; tissues from 10 mice were pooled and then subjected to ChIP assay for pELK-1. In each ChIP IP, qPCR analysis was conducted on both the endogenous and LacZ transgene as indicated in the figure. Asterisk indicates significant binding as mentioned in Figure 2D . C and D, Stably transfected rat aortic smooth muscle cells were plated at 1ϫ10 Ϫ4 , allowed to grow to confluence, and then switched to serumfree media for 3 days. After serum starvation, cells were treated with 20 ng/mL PDGF-BB (C) or 5 g/mL of POVPC (D) for 12 hours and then subject to ChIP analysis. Asterisk indicates significant binding as mentioned in Figure 2D . expression of the WT promoter but not the G/C Repressor mutant. Marked reductions in pELK-1 binding to the WT SM22␣ promoter LacZ transgene and endogenous SM22␣ promoter was observed after siRNA induced suppression of pELK-1 (Online Figure XA) . Moreover, of major interest, suppression of pELK-1 expression also markedly reduced KLF4 binding, indicating that it is required for binding of KLF4 to the SM22␣ promoter. Taken together, the preceding data provide direct evidence that mutation of the G/C Repressor attenuates binding of KLF4 and pELK-1, and, taken together with previous results, 16, 30, 31 suggest they act cooperatively to mediate repression of SM22␣ during SMC phenotypic switching in vivo and in vitro and that pELK-1 binding precedes KLF4 binding on the G/C Repressor element.
KLF4 and pELK-1 Interact Based on In Situ Proximity PLA Assays
We previously demonstrated that KLF4 and pELK-1 interact based on coimmunoprecipitation assays on homogenates of cultured SMC treated with POVPC. 31 To determine if KLF4 and pELK-1 interact within intact cells, we performed in situ DuoLink proximity ligation assays which permit detection of proteins located within approximately 40 nm within individual cells based on staining with secondary antibodies containing complementary single stranded DNA molecules (www.olink.com). Assays were performed in human coronary artery cells due to the availability of higher quality PLA-compatible antibodies for detection of human KLF4 and pELK-1 and because this would allow us to determine if the results seen in our rodent SMC lines also apply to human coronary SMC. Consistent with results of studies in rodent SMC lines, results of ChIP assays in human coronary SMC showed marked enrichment of KLF4 and pELK-1 binding but reduced SRF binding to the SM22␣ promoter after treatment with PDGF BB (Online Figure VI) . Moreover, results of the PLA assays showed evidence of interaction of KLF4 and pELK-1 after treatment with PDGF-BB ( Figure 5B ) or POVPC ( Figure 5C ). This increased interaction was blocked by treatment with the ERK inhibitors U1026 and PD98059, indicating that interaction is dependent on ELK-1 phosphorylation, which is critical for physical interaction of ELK-1 with SRF 16 and ELK-1 and KLF4. 31 Consistent with reduced SRF binding to the SM22␣ promoter in ChIP assays, PLA results showed reduced interaction of SRF with myocardin after treatment of cultured human coronary SMC with PDGF-BB or POVPC but was retained in cells treated with ERK inhibitors 39, 40 (Online Figures VII and VIII) . To our knowledge, these results are the first to actually show interaction of myocardin and SRF within intact cells and provide further evidence in support of our hypothesis that cooperative interactions of KLF4 and pELK-1 mediate G/C Repressor-dependent transcriptional repression during SMC phenotypic switching.
Hypomethylation of the SM22␣ Promoter After Carotid Ligation Is G/C Repressor Dependent and Mediated at Least in Part by Recruitment of HDAC2
Previously, we demonstrated that PDGF-BB-induced and POVPC-induced phenotypic switching in cultured SMC was 30 -32 To determine if similar mechanisms function in vivo, we performed H3 acetylation ChIP assays ( Figure 6A ) in WT and G/C Repressor mutant SM22␣ promoter LacZ transgenic mice 3 days after carotid ligation. Results showed marked reductions in H3 acetylation of the endogenous SM22␣ promoter and WT LacZ transgene but not the G/C Repressor mutant transgene. There was also marked enrichment of HDAC2 to the WT and endogenous SM22␣ promoters but not the G/C Repressor mutant SM22␣ promoter after ligation ( Figure 6B ). PDGF-BB or POVPC treatment of cultured SMC was associated with increased HDAC2 recruitment to the SM22␣ promoter that was also G/C Repressor dependent ( Figure 6C and 6D ). HDAC5 also showed increased binding in cultured SMC after PDGF-BB or POVPC treatment or in vivo after carotid ligation injury, but its binding was not affected by the G/C Repressor mutation (Online Figure XII) . Binding was selective for HDACs 2 and 5, since we saw no evidence for enhanced binding of HDACs 3, 4, or 7 in vitro or in vivo (Online Figure  XIII and Salmon and Owens, data not shown). Transient transfection assays of SM22␣ promoter-reporter genes with HDAC2 demonstrated decreased expression with the WT but not the G/C Repressor mutant (Online Figure V) . We also showed increased HDAC2 binding to the SM22␣ promoter in human coronary artery SMC after PDGF BB and POVPC treatment (Online Figure VI and data not shown). Furthermore, we were able to demonstrate that HDAC2 binding requires both pELK-1 and KLF4 via siRNA knock-downs and MEK/ERK inhibitor experiments (Online Figures IX, X, and XI). Finally, to determine if KLF4, pELK-1, and HDAC2 colocalize to the G/C Repressor element, triple sequential ChIP analyses were performed (Figure 7) . Sequential ChIP analyses demonstrated that KLF4, pELK-1, and HDAC2 were present within the same chromatin fragments consistent with formation of a higher-order complex. Significantly, we found that the G/C Repressor element was required for binding all 3 factors ( Figure 7A and 7C ). Finally, we performed additional ChIP analyses on the SM ␣-actin, SM-MHC, and c-Fos promoters in injured and noninjured mouse carotid artery samples 3 days after ligation injury to determine if pELK-1-KLF4-HDAC2-dependent transcriptional repression is applicable to multiple SMC genes (Figure 8 ). Results showed significant enrichment of KLF4, pELK-1, and HDAC2 binding to the SM ␣-actin and SM-MHC promoters after ligation injury and indicate that the mechanisms identified using the SM22␣ promoter as a model system are probably applicable to multiple CArG-dependent SMC marker genes. However, direct proof of this would require generation of G/C Repressor mutant promoter reporter transgenic mice for each of these genes. A and B , SM22 and SM22 G/C mut LacZ mice were subjected to right common carotid injury and then harvested 3 days after vascular injury; tissues from 10 mice were pooled and then subjected to ChIP assay for AcH3 (A) or HDAC2 (B). In each ChIP IP, qPCR analysis was conducted on both the endogenous and LacZ transgene as indicated in the figure. Asterisk indicates significant binding as mentioned in Figure  2D . C and D, Rat aortic smooth muscle cells were plated at 1ϫ10 Ϫ4 , allowed to grow to confluence, and then switched to serum-free media for 3 days. After serum starvation, cells were treated with 20 ng/mL PDGF-BB (C) or 5 g/mL of POVPC (D) for 12 hours and then subjected to ChIP analysis. Asterisk indicates significant binding as mentioned in Figure 2D .
Discussion
Herein we provide direct evidence that KLF4 mediates the effects of mutating the G/C Repressor element in suppression of SM22␣ during SMC phenotypic switching in vivo in response to vascular injury (Regan et al 41 and Figure 1 ) and atherogenesis. 42 Moreover, we provide evidence for a model wherein pELK-1 binds to the G/C Repressor region of the SM22␣ promoter and in turn recruits KLF4 and HDAC2, ultimately leading to epigenetic silencing of the gene locus mediated at least in part through histone deacetylation (Online Figure XIV) . Although the present studies focused primarily on a single SMC marker gene, SM22␣, we believe it is highly likely that similar mechanisms contribute to coordinate suppression of multiple SMC marker genes during SMC phenotypic switching both in vivo and in vitro given the following observations. First, we have previously shown that KLF4 overexpression markedly suppresses expression of all SMC marker genes examined to date. 40 Second, most SMC marker genes, but particularly CArG-SRFdependent genes including not only SM22␣ but also SM-MHC and SM ␣-actin, contain conserved G/C Repressor and/or ETS elements 41, 42, 61 (Online Figure IVA) . However, thus far they have only been shown to be functionally important for SM22␣ in vivo (Figure 1 and Regan et al 41 and Wamhoff et al 42 ) and in vitro 41, 42 and SM-MHC in vitro. 61 Third, inhibition of ELK-1 phosphorylation with MEK or ERK inhibitors has been shown to inhibit SMC phenotypic switching in cultured SMC by many labs, 16, 30, 31 although until the results presented herein there was a lack of clear evidence regarding the contribution of this pathway in vivo. Fourth, we have shown that conditional KLF4 knockout mice show delayed SMC phenotypic switching in vivo after ligation injury, 32 although it remains to be determined if this is a direct function of loss of KLF4 in SMC versus loss in other cell types including macrophages and endothelial cells, where it has been shown to regulate transitions in phenotype. 46 -50 Taken together, results are the first, and to date, the only published studies to our knowledge to identify a direct specific molecular mechanism that mediates SMC phenotypic switching in vivo, although further studies including SMCspecific conditional knockout of KLF4 will be required to conclusively show that cell autonomous KLF4 is required for SMC phenotypic switching in vivo. An additional unresolved issue is that it was not possible for us to distinguish the relative contributions of the ETS domain versus the G/C Repressor element, given the partial overlap of these elements, and the fact that it has been impossible to show binding of the higher-order pELK-1-KLF4-HDAC2 complex A, Rat aortic smooth muscle cells were prepared as mentioned previously. After serum starvation, cells were treated with 20 ng/mL PDGF-BB for 12 hours and then subject to ChIP analysis. Immunoprecipitations were performed in the sequence mentioned in the y-axis. B, IgG was used as a negative control within the sequence of triple immunoprecipitations. Reciprocal immunoprecipitation were performed but are not pictured. Asterisk indicates significant binding as mentioned in Figure  2D . C, Triple sequential ChIP analyses were performed as mentioned in A with a modification to the sequence of the pull-down as indicated on the y-axis. D, IgG was used as a negative control during the sequence of the pull-down as mentioned previously in B. except within intact chromatin or based on PLA assays as demonstrated herein. However, this may be irrelevant since, of course, mother nature did not dictate that these are indeed functionally distinct, and most importantly our studies provide what we believe is compelling evidence that the G/C Repressor mutation was remarkably specific in its effects on promoter function. For example, the mutation had no discernible effect on expression during development and maturation with identical expression patterns to both the WT SM22␣ promoter-LacZ transgene and the endogenous gene in our previous studies 41 and herein in adult SMC tissues (Figure 1 ). Consistent with these findings, we saw no effect of the G/C Repressor mutation on SRF binding, but it dramatically reduced KLF4, pELK-1, and HDAC2 binding after ligation injury in vivo, or POVPCinduced or PDGF-BB-induced phenotypic switching in cultured vascular SMC from mice, rats, and humans. Clearly, further studies will be required to determine the structural determinants of this promoter region that mediate recruitment of the pELK-1-KLF4 multiprotein complex.
A key unresolved question is the mechanism of activation of KLF4 expression in SMC, given this gene is epigenetically silenced in almost all differentiated somatic cells other than epithelial cells. 51, 52 The KLF4 promoter contains a number of conserved regulatory elements for AP-1, GATA-1, Sp1, NFB, and HLH factors, 53 but, as yet, no studies have directly assessed if these factors regulate KLF4 expression with the exception of our evidence showing that Sp1 bound the KLF4 promoter via ChIP assays. 45 Oct4 and other ESC factors may play a role given evidence that these factors reciprocally activate one another in ESCs. 54 There are a number of unresolved questions regarding mechanisms responsible for activation of KLF4 in SMC. First, what are the mechanisms and factors that activate expression of KLF4 in vivo during vascular injury or disease? Remarkably, despite widespread interest in this gene because of its involvement in production of iPS cells, as yet, no studies have identified sufficient regions of the promoter necessary to drive expression of the gene in vivo in transgenic mice, a prerequisite for studies elucidating mechanisms that induce it with injury-inflammation. Second, what mechanisms are responsible for reversing the stable epigenetic silencing of KLF4 during SMC phenotypic switching? Third, are other ESC factors involved in controlling SMC phenotypic switching? Fourth, do posttranslational modifications such as differential mRNA splicing, or chemical modifications such as sumoylation or acetylation regulate effects of KLF4? The latter is of interest since we have shown that TGF␤-induced expression of SM ␣-actin in cultured SMC is mediated in part through inactivation of KLF4 through protein sumoylation. 35 In summary, further studies are needed to determine if these factors regulate activation of KLF4 in SMC in vivo and if posttranslational modifications regulate KLF4 function.
In summary, results of the present studies provide direct evidence that KLF4 mediates phenotypic switching of SMCs in vivo during vascular injury and does so through binding to a G/C Repressor element. Moreover, our results support a model wherein there is sequential binding of pELK-1 and KLF4 followed by binding of HDAC2 to epigenetically silence the gene locus. Although the present studies have focused on studies of the SM22␣ gene, we believe that the results have broad significance for overall control of SMC phenotypic switching. However, further studies are needed to directly test if KLF4, pELK-1, and HDAC2 play similar roles in SMC phenotypic switching in disease models such as atherosclerosis.
